Last edition
News about "EirGenix "
Under the agreement, Transcenta will grant EirGenix a non-exclusive licence to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages.
EirGenix | 30/12/2025 | By News Bureau
EirGenix Signs Second Global Licensing Deal With Sandoz for Pertuzumab Biosimilar
EirGenix Inc., a Taiwan-based biopharmaceutical and CDMO company, has signed a second global exclusive licensing agreement with Sandoz AG for the commercialization of its pertuzumab biosimilar EG1206A, developed as an alternative to Roche’s Perjeta.
EirGenix | 14/11/2025 | By Darshana | 114
Sandoz and EirGenix Ink Global Licensing Deal for Pertuzumab Biosimilar
Sandoz, the global leader in affordable medicines, has signed a global license agreement with Taiwanese biotech company EirGenix to commercialise a proposed biosimilar of the oncology medicine pertuzumab. The milestone-based deal, valued at up to USD 152 million, includes an upfront payment and potential market-based incentives.
EirGenix | 13/11/2025 | By Dineshwori | 178
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy